Savolitinib vs Tepotinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Savolitinib · Orpathys
Marketed by AstraZeneca and partners
NCT05015608 · Phase 3 · completed
The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT04322890 (registry estimate)
Reported efficacy
Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)
Result source: NCT05261399
Tepotinib · Tepmetko
Marketed by Merck KGaA and partners
NCT02864992 · Phase 2 · active, not recruiting
The study was open-label and had no randomized comparator arm, so the reported tumor responses cannot be distinguished from outcomes that might have occurred with other treatment or without tepotinib. Although response was assessed by an independent review committee and results were reported for 337 participants, the primary endpoint was descriptive in this single-arm design.
Next expected readout: December 2027 · NCT06083857 (registry estimate)
Reported efficacy
Objective response rate (ORR) by independent review committee (IRC): ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months (not_applicable)
Result source: NCT02864992
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Savolitinib | Tepotinib |
|---|---|---|
| PFS, median | 8.2 vs 4.5avs chemotherapyNCT05015608 | 4.9 vs 4.4vs Pemetrexed and Cisplatin/CarboplatinNCT019829551 other result
|
| OS, median | —Not posted · NCT04923945 | 17.3 vs 19.5vs Pemetrexed and Cisplatin/CarboplatinNCT01982955 |
| ORR | 62.1%abNCT049239451 other result
| 45.2% vs 33.3%vs Pemetrexed and Cisplatin/CarboplatinNCT019829552 other results
|
| Duration of response, median | —Not posted · NCT04923945 | —Trial running · NCT06908993 |
PFS, median
- Savolitinib
- 8.2 vs 4.5avs chemotherapyNCT05015608
- Tepotinib
- 4.9 vs 4.4vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
1 other result
- 10.2 vs 4.3 NCT01982955
OS, median
- Savolitinib
- —Not posted · NCT04923945
- Tepotinib
- 17.3 vs 19.5vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
ORR
- Savolitinib
- 62.1%abNCT04923945
1 other result
- 39.2% NCT04923945
- Tepotinib
- 45.2% vs 33.3%vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
2 other results
- 33.3% NCT01982955
- 33.3% NCT01982955
Duration of response, median
- Savolitinib
- —Not posted · NCT04923945
- Tepotinib
- —Trial running · NCT06908993
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Savolitinib: 1 of 5 rows · Tepotinib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Savolitinib Rows use multiple source trials | Tepotinib |
|---|---|---|
| ORR responder rate · % of participants No placebo or comparator arm | 39.2%a,b,c,d,e NCT04923945 · Phase 3 · sponsor-reported, not registry data show 1 more dose62.1% NCT04923945 · Phase 3 · sponsor-reported, not registry data | 33.3% (n=12)500 mg + 250 mga,b,c,d,e NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose33.3% (n=6)300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Dropout rate | — | 0%500 mg + 250 mgf NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results0%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 0%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — | —500 mg + 250 mgf NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results—500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination —300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | — | 58.3%500 mg + 250 mgf NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results41.9%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 66.7%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | — | 500 mg + 250 mgf diarrhoea 83.3% dyspnoea exertional 41.7% fatigue 41.7% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results500 mg + 250 mg diarrhoea 58.1% oedema peripheral 38.7% amylase increased 35.5% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 300 mg + 250 mg amylase increased 66.7% diarrhoea 66.7% blood alkaline phosphatase increased 50% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 1/2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tepotinib
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Tepotinib's landscape